Main description:

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume Two: Diagnosis, Therapeutic Targets and Molecular Mechanisms for Hepatocellular Carcinoma Progression provides comprehensive information about ongoing research and clinical data surrounding liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. The volume discusses topics such as computational approaches for identification of biomarkers, enzymes and pathways of HCC, circulating and epigenetic biomarkers, drug resistance, metabolic pathways, and small molecule-target therapies. In addition, it discusses immunotherapies, immune check point inhibitors and nanotechnology-based therapies.

This book is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.

Contents:

1. Hepatocellular carcinoma diagnosis
2. Computational analysis of prognosisrelated genes in liver cancer
3. Computational approaches to identify biomarkers, enzymes, and pathways of hepatocellular carcinoma
4. Ribonucleic acid sequence analysis in deciphering hepatocellular carcinoma
5. Hepatocarcinogenesis and the role of next-generation sequencing in liver cancer
6. Liver cancer: the tumor microenvironment and associated pathways
7. Metabolic pathway-based target therapy to hepatocellular carcinoma: a computational approach
8. Targeting ion channels in hepatic cancer
9. Tyrosine kinases: their role in hepatocellular carcinoma
10. Role of transcription factors in hepatocellular carcinoma
11. Modulatory act of diverse transcriptional factors in liver carcinoma
12. Association of specificity protein 1 with hepatocellular carcinoma
13. Promising biomarkers for liver cancer
14. Molecular signaling and its role in drug resistance in hepatocellular carcinomas
15. Multidrug resistance, a major obstacle in hepatocellular carcinoma treatment: challenges and future perspectives
16. Proliferative signaling pathways in hepatocellular carcinoma
17. Targeting angiogenesis in hepatocellular carcinoma
18. Conventional and novel biomarkers for the diagnosis and prognosis of liver cancer
19. Updates on the staging and treatment of hepatocellular carcinoma
20. ROS-mediated pathways: potential role in hepatocellular carcinoma biology and therapy
21. Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes and therapeutic options
22. LKB1/STK11-mediated signal transduction in hepatocellular carcinoma